Tafinlar
Growth of the prostate cancer radiopharmaceutical was exponential following approval, but has now settled, leading Novartis to ramp up promotional efforts.
The drugmaker will seek regulatory approval for Scemblix in first-line Ph-positive CML and other precision drugs in the coming months.
The radioligand therapy hit roadblocks with supply constraints in early 2023, but a new manufacturing facility has since helped Novartis get back on track.
Novartis Focused on Radiopharmaceutical Expansion After Pluvicto, Lutathera Sales Both Grow in Q3
Premium
The Swiss drugmaker also reported revenue increases across other precision oncology products including its breast cancer drug Kisqali.
There was continued uptake of the CDK4/6 inhibitor among breast cancer patients, and the Swiss drugmaker resolved supply shortages for the prostate cancer radiopharmaceutical Pluvicto.